Radium-223 (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Radium-223" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

15doi.org

2^nd place

4^th place

10nih.gov

4^th place

13^th place

4worldcat.org

5^th place

7^th place

3zenodo.org

621^st place

1,261^st place

3harvard.edu

18^th place

44^th place

3web.archive.org

1^st place

3europa.eu

68^th place

182^nd place

2fda.gov

447^th place

792^nd place

1nuclearmasses.org

low place

1jstor.org

26^th place

53^rd place

1arxiv.org

69^th place

207^th place

1archive.org

6^th place

2^nd place

1bruland.info

low place

1snmjournals.org

low place

1prostatecancerinfolink.net

low place

1fiercebiotech.com

low place

1thepharmaletter.com

low place

archive.org

Lewis SL, Bucher L, Heitkemper M, Harding MM (2017). Medical-Surgical Nursing: Assessment and Management of Clinical Problems (edisi ke-10). Elsevier. ISBN 978-0-323-32852-4.

arxiv.org

Fry C, Thoennessen M (2013). "Discovery of actinium, thorium, protactinium, and uranium isotopes". Atomic Data and Nuclear Data Tables. 99 (3): 345–364. arXiv:1203.1194 . Bibcode:2013ADNDT..99..345F. doi:10.1016/j.adt.2012.03.002. ISSN 0092-640X.

bruland.info

Bruland O.S., Larsen R.H. (2003). Radium revisited. In: Bruland O.S., Flgstad T., editors. Targeted cancer therapies: An odyssey. University Library of Tromso, Ravnetrykk No. 29. ISBN 82-91378-32-0, hlm. 195–202. [1] Diarsipkan 21 April 2016 di Wayback Machine.

doi.org

Wang, M.; Audi, G.; Kondev, F. G.; Huang, W. J.; Naimi, S.; Xu, X. (2017). "The AME2016 atomic mass evaluation (II). Tables, graphs, and references" (PDF). Chinese Physics C. 41 (3): 030003–1—030003–442. doi:10.1088/1674-1137/41/3/030003.
Godlewski T (1905). "A new radio-active product from actinium". Nature. 71 (1839): 294–295. Bibcode:1905Natur..71..294G. doi:10.1038/071294b0. ISSN 0028-0836.
Godlewski T (1905). "V. Actinium and its successive products". The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science. 10 (55): 35–45. doi:10.1080/14786440509463342. ISSN 1941-5982.
Hahn, Otto (1906). "A new product of actinium". Nature. 73 (1902): 559–560. Bibcode:1906Natur..73..559H. doi:10.1038/073559b0. ISSN 0028-0836.
Kirby, Harold W. (1971). "The discovery of actinium". Isis. 62 (3): 290–308. doi:10.1086/350760. JSTOR 229943.
Fry C, Thoennessen M (2013). "Discovery of actinium, thorium, protactinium, and uranium isotopes". Atomic Data and Nuclear Data Tables. 99 (3): 345–364. arXiv:1203.1194 . Bibcode:2013ADNDT..99..345F. doi:10.1016/j.adt.2012.03.002. ISSN 0092-640X.
Marques IA, Neves AR, Abrantes AM, Pires AS, Tavares-da-Silva E, Figueiredo A, Botelho MF (July 2018). "Targeted alpha therapy using Radium-223: From physics to biological effects". Cancer Treatment Reviews. 68: 47–54. doi:10.1016/j.ctrv.2018.05.011. PMID 29859504.
Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. (Juni 2005). "First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases". Clinical Cancer Research. 11 (12): 4451–9. doi:10.1158/1078-0432.CCR-04-2244 . PMID 15958630.
Bruland ØS, Nilsson S, Fisher DR, Larsen RH (Oktober 2006). "High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?". Clinical Cancer Research. 12 (20 Pt 2): 6250s–6257s. doi:10.1158/1078-0432.CCR-06-0841 . PMID 17062709.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. (Juli 2007). "Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study". The Lancet. Oncology. 8 (7): 587–94. doi:10.1016/S1470-2045(07)70147-X. PMID 17544845.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. (18 Juli 2013). "Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer". New England Journal of Medicine. 369 (3): 213–223. doi:10.1056/NEJMoa1213755 . PMID 23863050.
Coleman, R; Aksnes, AK; Naume, B; Garcia, C; Jerusalem, G; Piccart, M; Vobecky, N; Thuresson, M; Flamen, P (13 April 2014). "A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease". Breast Cancer Research and Treatment. 145 (2): 411–418. doi:10.1007/s10549-014-2939-1 . PMC 4025174 . PMID 24728613.
Ueno, NT; Tahara, RK; Fujii, T; Reuben, JM; Gao, H; Saigal, B; Lucci, A; Iwase, T; Ibrahim, NK; Damodaran, S; Shen, Y; Liu, DD; Hortobagyi, G; Tripathy, D; Lim, B; Chasen, BA (2 December 2019). "Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer". Cancer Medicine. 9 (3): 1025–1032. doi:10.1002/cam4.2780 . PMC 6997080 . PMID 6997080.
Henriksen G, Hoff P, Larsen RH (Mei 2002). "Evaluation of potential chelating agents for radium". Applied Radiation and Isotopes. 56 (5): 667–71. doi:10.1016/s0969-8043(01)00282-2. PMID 11993940.
Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS, Larsen RH (Mei 2004). "Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides". Nuclear Medicine and Biology. 31 (4): 441–9. doi:10.1016/j.nucmedbio.2003.11.004. PMID 15093814.

europa.eu

ema.europa.eu

"Xofigo Summary of Product Characteristics" (PDF). European Medicines Authority. Bayer. 11 Oktober 2018. Diakses tanggal 26 Juni 2022.
"Xofigo". 17 September 2018.
"EMA restricts use of prostate cancer medicine Xofigo". Badan Pengawas Obat Eropa. 28 September 2018.

fda.gov

accessdata.fda.gov

FDA Access Data on Xofigo (Radium-223 dichloride)

fda.gov

"FDA approves new drug for advanced prostate cancer". US FDA. Diarsipkan dari versi asli tanggal 7 Juni 2013.

fiercebiotech.com

"FDA OKs pinpoint prostate cancer radiation drug Xofigo from Bayer, Algeta". Diarsipkan dari versi asli tanggal 22 Januari 2014. Diakses tanggal 26 Juni 2022.

harvard.edu

adsabs.harvard.edu

Godlewski T (1905). "A new radio-active product from actinium". Nature. 71 (1839): 294–295. Bibcode:1905Natur..71..294G. doi:10.1038/071294b0. ISSN 0028-0836.
Hahn, Otto (1906). "A new product of actinium". Nature. 73 (1902): 559–560. Bibcode:1906Natur..73..559H. doi:10.1038/073559b0. ISSN 0028-0836.
Fry C, Thoennessen M (2013). "Discovery of actinium, thorium, protactinium, and uranium isotopes". Atomic Data and Nuclear Data Tables. 99 (3): 345–364. arXiv:1203.1194 . Bibcode:2013ADNDT..99..345F. doi:10.1016/j.adt.2012.03.002. ISSN 0092-640X.

jstor.org

Kirby, Harold W. (1971). "The discovery of actinium". Isis. 62 (3): 290–308. doi:10.1086/350760. JSTOR 229943.

nih.gov

ncbi.nlm.nih.gov

Marques IA, Neves AR, Abrantes AM, Pires AS, Tavares-da-Silva E, Figueiredo A, Botelho MF (July 2018). "Targeted alpha therapy using Radium-223: From physics to biological effects". Cancer Treatment Reviews. 68: 47–54. doi:10.1016/j.ctrv.2018.05.011. PMID 29859504.
Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. (Juni 2005). "First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases". Clinical Cancer Research. 11 (12): 4451–9. doi:10.1158/1078-0432.CCR-04-2244 . PMID 15958630.
Bruland ØS, Nilsson S, Fisher DR, Larsen RH (Oktober 2006). "High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?". Clinical Cancer Research. 12 (20 Pt 2): 6250s–6257s. doi:10.1158/1078-0432.CCR-06-0841 . PMID 17062709.
Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH (Februari 2003). "Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice". Journal of Nuclear Medicine. 44 (2): 252–9. PMID 12571218.
Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. (Juli 2007). "Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study". The Lancet. Oncology. 8 (7): 587–94. doi:10.1016/S1470-2045(07)70147-X. PMID 17544845.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. (18 Juli 2013). "Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer". New England Journal of Medicine. 369 (3): 213–223. doi:10.1056/NEJMoa1213755 . PMID 23863050.
Coleman, R; Aksnes, AK; Naume, B; Garcia, C; Jerusalem, G; Piccart, M; Vobecky, N; Thuresson, M; Flamen, P (13 April 2014). "A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease". Breast Cancer Research and Treatment. 145 (2): 411–418. doi:10.1007/s10549-014-2939-1 . PMC 4025174 . PMID 24728613.
Ueno, NT; Tahara, RK; Fujii, T; Reuben, JM; Gao, H; Saigal, B; Lucci, A; Iwase, T; Ibrahim, NK; Damodaran, S; Shen, Y; Liu, DD; Hortobagyi, G; Tripathy, D; Lim, B; Chasen, BA (2 December 2019). "Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer". Cancer Medicine. 9 (3): 1025–1032. doi:10.1002/cam4.2780 . PMC 6997080 . PMID 6997080.
Henriksen G, Hoff P, Larsen RH (Mei 2002). "Evaluation of potential chelating agents for radium". Applied Radiation and Isotopes. 56 (5): 667–71. doi:10.1016/s0969-8043(01)00282-2. PMID 11993940.
Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS, Larsen RH (Mei 2004). "Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides". Nuclear Medicine and Biology. 31 (4): 441–9. doi:10.1016/j.nucmedbio.2003.11.004. PMID 15093814.

nuclearmasses.org

Wang, M.; Audi, G.; Kondev, F. G.; Huang, W. J.; Naimi, S.; Xu, X. (2017). "The AME2016 atomic mass evaluation (II). Tables, graphs, and references" (PDF). Chinese Physics C. 41 (3): 030003–1—030003–442. doi:10.1088/1674-1137/41/3/030003.

prostatecancerinfolink.net

Full data report from the ALSYMPCA trial of radium-223 presented

snmjournals.org

jnm.snmjournals.org

Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH (Februari 2003). "Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice". Journal of Nuclear Medicine. 44 (2): 252–9. PMID 12571218.

thepharmaletter.com

"Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo". The Pharma Letter. 16 Mei 2013.

web.archive.org

Bruland O.S., Larsen R.H. (2003). Radium revisited. In: Bruland O.S., Flgstad T., editors. Targeted cancer therapies: An odyssey. University Library of Tromso, Ravnetrykk No. 29. ISBN 82-91378-32-0, hlm. 195–202. [1] Diarsipkan 21 April 2016 di Wayback Machine.
"FDA OKs pinpoint prostate cancer radiation drug Xofigo from Bayer, Algeta". Diarsipkan dari versi asli tanggal 22 Januari 2014. Diakses tanggal 26 Juni 2022.
"FDA approves new drug for advanced prostate cancer". US FDA. Diarsipkan dari versi asli tanggal 7 Juni 2013.

worldcat.org

Godlewski T (1905). "A new radio-active product from actinium". Nature. 71 (1839): 294–295. Bibcode:1905Natur..71..294G. doi:10.1038/071294b0. ISSN 0028-0836.
Godlewski T (1905). "V. Actinium and its successive products". The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science. 10 (55): 35–45. doi:10.1080/14786440509463342. ISSN 1941-5982.
Hahn, Otto (1906). "A new product of actinium". Nature. 73 (1902): 559–560. Bibcode:1906Natur..73..559H. doi:10.1038/073559b0. ISSN 0028-0836.
Fry C, Thoennessen M (2013). "Discovery of actinium, thorium, protactinium, and uranium isotopes". Atomic Data and Nuclear Data Tables. 99 (3): 345–364. arXiv:1203.1194 . Bibcode:2013ADNDT..99..345F. doi:10.1016/j.adt.2012.03.002. ISSN 0092-640X.

zenodo.org

Godlewski T (1905). "A new radio-active product from actinium". Nature. 71 (1839): 294–295. Bibcode:1905Natur..71..294G. doi:10.1038/071294b0. ISSN 0028-0836.
Godlewski T (1905). "V. Actinium and its successive products". The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science. 10 (55): 35–45. doi:10.1080/14786440509463342. ISSN 1941-5982.
Hahn, Otto (1906). "A new product of actinium". Nature. 73 (1902): 559–560. Bibcode:1906Natur..73..559H. doi:10.1038/073559b0. ISSN 0028-0836.